Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The trial is a multicenter, prospective, block randomized, open label, blinded-endpoint
(PROBE) controlled design. Patients with acute ischemic stroke due to large vessel occlusion
within 4.5-24 hours of symptom onset (including wake-up stroke and unwitnessed stroke) will
be randomized 1:1 to 0.25mg/kg intravenous tenecteplase or standard medical treatment.